10-Q: Amwell Narrows Losses, Boosts Subscription Revenue

Amwell reported significantly reduced net losses and strong subscription revenue growth in Q2 2025, driven by strategic divestitures and cost-cutting measures.

Summary

• Net loss attributable to American Well Corporation significantly improved to $19.7 million for the three months ended June 30, 2025, compared to $49.9 million for the same period in 2024, a 61% reduction.
• Revenue increased by 13% to $70.9 million for the three months ended June 30, 2025, up from $62.8 million in the prior year, primarily driven by a $12.9 million increase in platform subscription revenue.
• Adjusted EBITDA improved substantially to a loss of $4.7 million for Q2 2025, compared to a loss of $35.0 million in Q2 2024.
• The company completed the divestiture of its APC Business on January 8, 2025, generating $20.4 million in proceeds and a gain of $10.7 million.
• Total costs and operating expenses decreased by 21% to $91.3 million for Q2 2025, down from $115.2 million in Q2 2024, largely due to headcount reductions across various departments.
• Overall quarterly visits performed by clients decreased to 1.165 million in Q2 2025 from 1.5 million in Q2 2024.
• The joint venture CCAW, JV LLC with Cleveland Clinic will wind down during the second half of 2025.
• Cash and cash equivalents stood at $219.1 million as of June 30, 2025, a decrease from $228.3 million at December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company continues to incur losses and overall visit volumes have declined, the significant reduction in net loss and operating expenses, coupled with strong subscription revenue growth and strategic divestiture, indicates a positive trajectory towards profitability and a more focused business model. The cash position is deemed sufficient for the next 12 months, but the large accumulated deficit and potential need for future capital raise temper the overall positive outlook.

Positives

• Net loss attributable to American Well Corporation decreased by 61% to $19.7 million for the three months ended June 30, 2025, from $49.9 million in the prior year.
• Adjusted EBITDA showed significant improvement, reducing the loss to $4.7 million in Q2 2025 from $35.0 million in Q2 2024.
• Platform subscription revenue increased by $12.9 million, demonstrating strong growth in the core enterprise software business.
• Successful divestiture of the APC Business generated $20.4 million in cash proceeds and a $10.7 million gain, streamlining service offerings.
• Operating expenses saw substantial reductions across all categories: Cost of revenue decreased by 21%, Research and development by 12%, Sales and marketing by 32%, and General and administrative by 26%, primarily due to headcount reductions and cost savings measures.
• Net cash used in operating activities improved significantly to $29.8 million for the six months ended June 30, 2025, compared to $81.5 million for the same period in 2024.
• The company maintains a healthy cash and cash equivalents balance of $219.1 million and has no outstanding debt.

Negatives

• The company continues to operate at a net loss of $19.7 million for Q2 2025 and has an accumulated deficit of $2.004 billion as of June 30, 2025.
• Overall quarterly visits performed by clients decreased to 1.165 million in Q2 2025 from 1.5 million in Q2 2024, representing a decline in utilization.
• Visit revenue decreased by $6.3 million in Q2 2025 due to the APC divestiture, despite partial offsets from other programs.
• The joint venture CCAW, JV LLC with Cleveland Clinic is winding down, indicating a change in a strategic partnership.
• Two clients accounted for a significant concentration of outstanding accounts receivable (50% and 12%) and total revenue (33% and 26%) for Q2 2025, posing client concentration risk.
• Legal costs increased by $2.2 million in Q2 2025 as the company continues diligence and discovery related to various ongoing legal matters.

Risks

• Weak growth and increased volatility in the digital care market could adversely affect financial results.
• A history of losses and the risk of not achieving profitability persist.
• Inability to adapt to rapid technological changes could impact competitiveness.
• Reliance on a limited number of significant clients poses a risk if their business is lost.
• Increased competition from existing and potential new participants in the healthcare industry could erode market share.
• Changes in healthcare laws, regulations, or trends could impact operations and profitability.
• Failure to comply with regulations concerning personally identifiable information and personal health industry data could lead to significant liability.
• Slower than expected growth in patient adoption of digital care and platform usage by clients or patients could hinder revenue growth.
• Inability to grow the base of affiliated and non-affiliated providers sufficient to serve patient demand.
• The risk that maintained insurance may not fully cover all potential exposures.
• Uncertainty regarding the continuation of the Defense Health Agency relationship beyond July 2026 with comparable financial terms.

Future Outlook

The company expects research and development, sales and marketing, and general and administrative expenses to decrease in the current year and then remain relatively flat in future periods, driven by cost savings measures. Management believes existing cash and cash equivalents will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months. The joint venture with Cleveland Clinic (CCAW, JV LLC) is expected to wind down in the second half of 2025. The company continues to evaluate potential strategic transformation actions and may incur additional related costs in future periods.

Management Comments

• "Streamlining our service offerings will enable us to focus our resources on the Converge platform, strategic customers, and our path to profitability."
• "We believe increased spending in prior years was a temporary investment to accelerate development of a more scalable and economically beneficial solution that will properly position the Company to benefit in the long term and have seen marked decline during 2025 as we return to normal levels of spend in future periods."
• "We expect research and development expense to decrease over the next year and then to remain flat in future periods."
• "We will continue to invest appropriately in sales expenses as we look to grow with new prospects and expand the business of our existing clients."
• "We expect sales and marketing expense to decrease in the current year and then to remain flat in future periods."
• "We expect our general and administrative expenses to decrease in the current year and then remain relatively flat in future periods, based on the impact of cost savings measure put in place throughout 2024."
• "We believe that our existing cash and cash equivalents will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months from the issuance date of the financial statements."

Industry Context

The company operates in the evolving digital care market, which is experiencing increasing acceptance and adoption. While the COVID-19 pandemic led to a loosening of regulatory requirements that boosted digital care services, some flexibilities, such as Medicare reimbursement waivers, are extended only through September 30, 2025. The company's focus on its Amwell Converge™ platform aligns with the broader industry trend towards integrated hybrid care delivery models that blend in-person, virtual, and automated care experiences. The investment in AI development (Aingelz, Inc.) indicates an effort to leverage emerging technologies to enhance its offerings and maintain competitiveness in a rapidly changing healthcare technology landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. However, the company's strategic shift towards its 'Converge' platform and focus on enterprise solutions for health plans and health systems is consistent with a trend among leading digital health providers to offer more comprehensive, integrated solutions rather than standalone telehealth services.
• The significant reduction in operating losses and improvement in Adjusted EBITDA suggest a positive trajectory towards profitability, which is a key indicator of financial health in the growth-oriented digital health sector, where many companies are still scaling and incurring losses.
• The decrease in overall visit volumes, while partially attributed to divestiture, warrants attention as sustained growth in utilization is crucial for digital care platforms. Industry leaders typically aim for consistent or increasing engagement metrics.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that are expected to have a material adverse effect on its consolidated financial position, results of operations, or cash flows.
• Legal costs increased by $2.2 million for the three months ended June 30, 2025, and $2.8 million for the six months ended June 30, 2025, as the company continues diligence and discovery related to various ongoing legal matters.

Related Party Transactions

• Cleveland Clinic: A related party due to a board member serving as an executive advisor. The company held $86k in current deferred revenue and $43k in amounts due from Cleveland Clinic as of June 30, 2025. Revenue recognized from contracts with Cleveland Clinic was $67k for Q2 2025 and $129k for H1 2025.
• CCAW, JV LLC: A joint venture with Cleveland Clinic where the company holds a minority interest. The company held $61k in current deferred revenue and had $1,196k due from CCAW, JV LLC as of June 30, 2025. Revenue recognized from contracts with CCAW, JV LLC was $766k for Q2 2025 and $1,136k for H1 2025. The joint venture is winding down in H2 2025.

Stakeholder Impact

• Shareholders: Experienced a 1-for-20 reverse stock split. Benefit from significantly reduced net losses and improved Adjusted EBITDA, indicating a stronger path to profitability. However, the company still operates at a loss and has a large accumulated deficit.
• Employees: Impacted by headcount reductions across various departments (22% in cost of revenue, 12% R&D, 41% S&M, 27% G&A) as part of strategic transformation actions.
• Customers (Health Plans, Health Systems): Benefit from the company's focus on the Amwell Converge platform and strategic customers, aiming for improved and more robust healthcare solutions. The divestiture of the APC Business may affect some customers previously served by that segment.
• Providers (AMG network): The company's clinical affiliate, AMG, continues to provide services, with AMG providers accounting for an increased share of total visits (27% in H1 2025 vs. 24% in H1 2024), despite an overall decrease in total visit volumes.
• Creditors: The company has no debt and believes its existing cash and cash equivalents are sufficient for working capital and capital expenditure needs for at least the next 12 months, indicating low immediate credit risk.

Next Steps

• The joint venture CCAW, JV LLC will wind down during the second half of 2025.
• The company will evaluate the impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on its forecasted annual effective tax rate in future periods.
• Management will continue to evaluate potential strategic transformation actions and may incur additional related costs in future periods.
• The company will continue to invest appropriately in sales expenses to grow with new prospects and expand existing client business.
• The company will continue diligence and discovery related to various ongoing legal matters.

Key Dates

Recommendation

The company demonstrated significant financial improvements, notably a substantial reduction in net losses and a positive shift in Adjusted EBITDA, driven by effective cost-cutting measures and a strategic divestiture. Subscription revenue growth is strong, indicating success in its core platform business. However, the company remains unprofitable with a large accumulated deficit, and overall visit volumes have declined. While the strategic focus and cost efficiencies are positive, the continued losses and client concentration risks suggest a 'hold' position for investors, awaiting sustained profitability and consistent growth in key metrics before a more aggressive stance.

Keywords

Telehealth, Digital Health, Virtual Care, Healthcare Technology, SaaS, Health Systems, Health Plans, Amwell Converge, Financial Results, SEC Filing, 10-Q